Last reviewed · How we verify

emtricitabine [FTC]/tenofovir [TDF]

Tibotec, Inc · FDA-approved active Small molecule

emtricitabine [FTC]/tenofovir [TDF] is a Nucleoside reverse transcriptase inhibitor (NRTI) combination Small molecule drug developed by Tibotec, Inc. It is currently FDA-approved for HIV-1 infection (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).

This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.

This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).

At a glance

Generic nameemtricitabine [FTC]/tenofovir [TDF]
SponsorTibotec, Inc
Drug classNucleoside reverse transcriptase inhibitor (NRTI) combination
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Emtricitabine and tenofovir are both nucleoside/nucleotide analogs that inhibit HIV reverse transcriptase, the enzyme the virus uses to convert its RNA genome into DNA for integration into host cells. By blocking this critical step in the HIV replication cycle, the combination reduces viral load and slows disease progression. This fixed-dose combination is commonly used as part of antiretroviral therapy regimens.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about emtricitabine [FTC]/tenofovir [TDF]

What is emtricitabine [FTC]/tenofovir [TDF]?

emtricitabine [FTC]/tenofovir [TDF] is a Nucleoside reverse transcriptase inhibitor (NRTI) combination drug developed by Tibotec, Inc, indicated for HIV-1 infection (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).

How does emtricitabine [FTC]/tenofovir [TDF] work?

This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.

What is emtricitabine [FTC]/tenofovir [TDF] used for?

emtricitabine [FTC]/tenofovir [TDF] is indicated for HIV-1 infection (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).

Who makes emtricitabine [FTC]/tenofovir [TDF]?

emtricitabine [FTC]/tenofovir [TDF] is developed and marketed by Tibotec, Inc (see full Tibotec, Inc pipeline at /company/tibotec-inc).

What drug class is emtricitabine [FTC]/tenofovir [TDF] in?

emtricitabine [FTC]/tenofovir [TDF] belongs to the Nucleoside reverse transcriptase inhibitor (NRTI) combination class. See all Nucleoside reverse transcriptase inhibitor (NRTI) combination drugs at /class/nucleoside-reverse-transcriptase-inhibitor-nrti-combination.

What development phase is emtricitabine [FTC]/tenofovir [TDF] in?

emtricitabine [FTC]/tenofovir [TDF] is FDA-approved (marketed).

What are the side effects of emtricitabine [FTC]/tenofovir [TDF]?

Common side effects of emtricitabine [FTC]/tenofovir [TDF] include Nausea, Diarrhea, Headache, Fatigue, Lactic acidosis (rare but serious), Hepatotoxicity.

What does emtricitabine [FTC]/tenofovir [TDF] target?

emtricitabine [FTC]/tenofovir [TDF] targets HIV reverse transcriptase and is a Nucleoside reverse transcriptase inhibitor (NRTI) combination.

Related